News in brief

ChromaDex QC and R&D facility in Longmont, Colorado obtains ISO/IEC 17025:2017 Accreditation

By Stephen Daniells contact

- Last updated on GMT

© Getty Images / gorodenkoff
© Getty Images / gorodenkoff

Related tags: laboratory standards, Nicotinamide riboside, reference standards

California-based ChromaDex Corp. has achieved accreditation to the requirements of ISO/IEC 17025:2017 for its quality control and R&D facility in Longmont, CO, including the testing and analysis of its Tru Niagen product, ingredients, and reference standards.

The American Association for Laboratory Accreditation (A2LA) performed the accreditation to the ISO/IEC 17025:2017 quality standard for laboratory testing. ISO 17025 accreditation validates the technical proficiency of the state-of-the-art ChromaDex laboratory and its proven ability to consistently generate highly accurate, scientifically defensible product quality data that is traceable to and compliant with international standards, said the company in a release.

“This latest accreditation recognizes ChromaDex’s consistency in meeting the highest international standards in quality control,”​ said Rob Fried, ChromaDex CEO. “Our global partners such as Nestlé have learned to expect these designations along with world-class clinical data.”

ChromaDex previously achieved ISO 17025 accreditation for its Boulder laboratory (which it since sold to LabCorp​).

“ChromaDex has always adhered to high standards, but actually, this is our first time obtaining this accreditation for the Longmont lab,” ​a spokesperson told NutraIngredients-USA. “To achieve the accreditation, we developed laboratory practices and procedures that follow the requirements for CFR part 111 (cGMP for Dietary Supplements) as well as CFR part 117 HACCP (Hazard Analysis and Critical Control Points) for food ingredients.”

Niagen (nicotinamide riboside) is tested under ChromaDex’s ISO/IEC 17025:2017 accreditation, said the company. It is the only commercially available NR that has twice been successfully reviewed under U.S. FDA’s new dietary ingredient (NDI) notification requirement and successfully notified to the FDA as generally recognized as safe (GRAS).

The ingredient also has regulatory approval in Canada, Australia, and the European Union.

Dr Andrew Shao, ChromaDex Sr VP of Global Scientific & Regulatory Affairs, added: “The quality and reliability of our products is affirmed through this process. This accreditation helps provide health regulators with confidence in the quality and science behind our products in markets across the globe.”

Related topics: Suppliers

Related news

Follow us


View more